CLOVERNA

Executive Summary

Cloverna is a Japanese biotechnology company pioneering RNA-targeted drug discovery via a proprietary CRISPR/dCas13-based platform to identify novel non-coding RNA interactions and develop selective RNA-interaction modifiers (SRiMs) as oligonucleotide therapeutics. Founded in 2019 and headquartered in Tokyo, the company focuses on rare and intractable diseases with high unmet medical needs. Operating at a preclinical stage with 10-50 employees, Cloverna has not yet disclosed funding, valuation, or disclosed significant partnerships. The company's approach addresses the underexplored non-coding RNA space, offering potential for first-in-class therapies in indications where traditional modalities have failed. However, as a private, preclinical-stage entity, it carries significant execution risk and lacks near-term revenue or clinical validation. The conviction score reflects an early-stage, high-risk, high-reward profile, with upside contingent on platform validation and advancement to IND.

Upcoming Catalysts (preview)

• H1 2027Lead program nomination and preclinical proof-of-concept data40% success
• 2027Series A financing or strategic partnership50% success
• H2 2028IND/CTA filing for lead candidate30% success